0
World
As China’s biotech firms shift gears, can AI floor the accelerator?
April 18, 2026
Scroll
Posted 3 hours ago by
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US18.5 billion and US5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US745 million.
Under the terms of the deal, the Beijing-based Haisco granted US...
South China Morning Post
Coverage and analysis from Hong Kong. All insights are generated by our AI narrative analysis engine.
Hong Kong
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.